Skip to main content

Table 2 Comparison between anti-PM/Scl-75 antibody-positive versus-negative patients

From: Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients

Disease manifestation

anti-PM/Scl-75-positive

(n = 29)

anti-PM/Scl-75-negative

(n = 251)

P value

Sensitivity, percentagea

Specificity, percentageb

mRSSc

9.0 (11.3)

7.2 (7.4)

0.017

NA

NA

Digital ulcersd

19 (65.5)

93 (37.1)

0.005

17

94

Lung fibrosisd

16 (55.2)

82 (32.7)

0.023

16.3

92.9

Restrictive lung diseased

18 (62.1)

81 (32.3)

0.001

18.2

94.8

DLCO-SBc

65.7 (18.1)

73.7 (20.7)

0.091

NA

NA

Mean FVCc

80.0 (14.1)

93.6 (19.2)

<0.005

NA

NA

PAHd

2 (6.9)

58 (23.1)

0.054

3.3

87.7

Contracturesd

23 (79.3)

149 (59.4)

0.044

13.4

94.4

CK elevationd

10 (34.5)

27 (10.8)

0.002

27

92.2

Muscle atrophyd

19 (65.5)

111 (44.2)

0.032

14.6

93.3

Colon involvementd

7(24.1)

112 (44.6)

0.046

5.9

86.3

Disease activityc

2.0 (1.2)

1.5 (1.3)

0.037

NA

NA

  1. Clinical differences between antibody-positive and -negative patients were shown only when P values of below 0.1 were detected. aProbability that patients with the respective disease manifestation are anti-PM/Scl-75-positive; for example, sensitivity of anti-PM/Scl-75 (digital ulcers) = 19/(19 + 93) = 0.17. bProbability that patients without the respective disease manifestation are anti-PM/Scl-75-negative; for example, specificity of anti-PM/Scl-75 (digital ulcers) = (251 - 93)/(29 - 19 + 251 - 93) = 0.94. cValues displayed are medians (standard deviations). dValues displayed are numbers of patients (percentages). CK, creatine kinase; DLCO-SB, predicted diffusion capacity of a single breath; FVC, forced vital capacity; mRSS, modified Rodnan skin score; NA, not applicable; PAH, pulmonary arterial hypertension.